Published in Vaccine Weekly, September 22nd, 2004
This follows an earlier statement by the EMEA on March 22, 2004, concerning supply shortages.
While delivery capacity is being resumed, the EMEA and its committee for medicinal products for human use (CHMP) recommend that the appropriate national authorities implement the following revised proposals on the use of Prevenar:
High-risk children (those with medical conditions such as splenic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly